英文药名：EPOCELIN Suppositories(Ceftizoxime Sodium) 中文药名：头孢唑肟钠坐剤 生产厂家：長生堂製薬 エポセリン坐剤125／エポセリン坐剤250 通用药名：CEFTIZOXIME SODIUM 别　　名：去甲噻肟头孢菌素，头孢甲噻肟，安普西林，安保速灵, Epocelin, CZX, Epocerin, FK749, FR13749, SK F88372-Z, Ceftix, Cefizox 开发单位：藤泽药品工业株式会社 (日本) 首次上市：1982年，日本 治疗类别名称 合成头孢菌素制剂 商標名 EPOCELIN Suppositories 125 EPOCELIN Suppositories 250 一般名 セフチゾキシムナトリウム(Ceftizoxime Sodium) 化学名 Ｍonosodium(6R ,7R )-7-[(Z )-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetylamino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 分子式 Ｃ13Ｈ12Ｎ5ＮａＯ5Ｓ2 分子量 405.38 構造式 性状 头孢唑肟钠为白色结晶或结晶性粉末至浅黄色。非常易溶于水，微溶于甲醇，并在乙醇中（95）几乎不溶。 操作注意事项 1.理想的是被存储在15℃或以下。 2.铝袋开封后，由于可以通过光照和水分变黄，最好在阴凉避光处存放 药效药理 1. 抗菌作用 (1) 抗菌谱的革兰氏阳性菌，和在大范围的革兰氏阴性细菌，特别是链球菌属的革兰氏阳性球菌，肺炎链球菌，大肠杆菌是一种革兰氏阴性杆菌，克雷伯氏菌属，变形杆菌，摩根Morugani，普罗维登斯菌属，流感嗜血杆菌，等等除了显示出对，显示枸橼酸杆菌，肠杆菌属，沙雷氏菌属，消化链球菌，抗厌氧菌包括杆菌和普氏菌Meraninojenika的优异的抗菌活性很强的抗菌活性。操作格式是杀菌。 (2) 稳定对β-内酰胺酶来生产各种类型的细菌，它显示出优异的抗菌活性对β-内酰胺酶生产菌。 2. 作用机序 作用机制是细菌细胞壁的合成的抑制，具有用于1b中青霉素结合蛋白（PBP）的最强的亲和力，随后1a中，3。此外，革兰氏阴性细菌的外膜的渗透性良好。 适应病症 头孢菌类抗生素。对革兰阳性菌、阴性菌有广谱抗菌作用，特别是对革兰阳性球菌中的肺炎球菌，链球菌属(肠球菌除外)、革兰阴性杆菌中的大肠杆菌、克雷伯菌属、奇异变形杆菌、吲哚阳性变形杆菌、流感杆菌等显示强效的抗菌活力，对多种头孢菌类抗生素显示耐药性的柠檬酸细菌属、肠杆菌属、沙雷属以及拟杆菌属等厌氧菌也显示良好的抗菌作用。作用方式为杀菌。由于对各种细菌产生的β-内酰胺酶稳定，对β-内酰胺酶产生菌也显示抗菌活力。用于对本品敏感的链球菌属(肠球菌除外)、肺炎球菌、流感杆菌、大肠杆菌、克雷伯菌属、变形杆菌属，沙雷菌属、肠杆菌属、柠檬酸细菌属，消化球菌属、消化链球菌属、拟杆菌属所引起的下列感染:败血症、感染性的内膜炎、创伤、烧伤的继发感染，支气管炎，支气管扩张症感染、慢性呼吸系统疾病的继发感染、肺炎、肺化脓性疾病、脓胸、胆囊炎、胆管炎、腹膜炎、肾盂肾炎、膀胱炎、前列腺炎、子宫附件炎、子宫内感染、骨盆死腔炎、脑膜炎。 用法与用量 每天1次20-70毫克按头孢唑肟体重儿童（效价），分成三到四倍的千克插入肛门。 此外，增加或减少取决于患者的年龄和症状。 包装规格 栓剂 125*20个/盒 250*20个/盒 制造厂商 長生堂製薬 完整资料附件：http://www.info.pmda.go.jp/go/pack/6132700J1022_4_03/ EPOCELIN Suppositories 125/250（Ceftizoxime Sodium） Name of drug classification Synthetic cephalosporin preparations Sales name Epo-serine suppository 125 Common name Ceftizoxime sodium, Ceftizoxime Sodium (JAN) Chemical name 4-yl) -2- (methoxyimino) acetylamino] -8-oxo-5-thia-1-azabicyclo [4.2.0] Oct-2-ene-2-carboxylate Molecular formula C13 H12 N 5 NaO 5 S 2 Molecular weight 405.38 Property White to pale yellow crystals or crystalline powders. It is very soluble in water, it is difficult to dissolve in methanol, and it hardly dissolves in ethanol (95). composition Ingredient · Content (in 1) Japan Ceftizoxime sodium 125 mg (potency) Additive Sodium caprate, hard fat Contraindications Patients with a history of shock due to ingredients of this drug Indication or effect Adaptive fungal species Ceftiosoxime-sensitive streptococcus, pneumococcus, Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Serratia, Proteus, Morganella morganii, Providencia, Haemophilus influenzae, Peptostreptococcus, Bacteroides, Prevotella Melaninogenica Indication Acute bronchitis, pneumonia, secondary infections of chronic respiratory lesions, cystitis, pyelonephritis Usually, 20 to 70 mg (titer) per day as ceftiosoxime per kg body weight is inserted into the anus in 3 to 4 divided doses. Incidentally, it will be increased or decreased according to your age and symptoms. When using this drug, in order to prevent the development of resistant bacteria etc., in principle, sensitivity should be confirmed and administration should be limited to the minimum period necessary for treatment of the disease. For patients with advanced renal impairment, blood levels will be sustained, so the dose should be reduced according to the extent of renal impairment and used at intervals of administration. Careful Administration Patients with a history of hypersensitivity to penicillin antibiotics A patient having a constitution that is likely to cause an allergic symptom such as bronchial asthma, rash, urticaria or the like by himself, parents or brothers Patients with advanced renal impairment (see "Usage notes related to usage and dose") Patients with bad oral intake or patients with parenteral nutrition, patients with poor general condition [Vitamin K deficiency symptoms may occur, so observe thoroughly] Serious side effects shock Because shock (less than 0.1%) may occur, observation is done sufficiently, and when discomfort, mouth abnormality feeling, wheezing, dizziness, bowel movement, tinnitus, sweating etc. appears, administration is stopped and appropriate treatment To do. Anaphylactoid symptoms Since anaphylactoid symptoms (dyspnea, general flushing, angioedema, urticaria etc.) (may be less than 0.1%) may appear, observation should be done sufficiently, if abnormality is found discontinue administration and appropriate Take action. Blood disorder Hemolytic anemia (less than 0.1%, early symptoms: fever, hemoglobinuria, anemia), pancytopenia (less than 0.1%), agranulocytosis (less than 0.1%, early symptoms: fever, sore throat, headache, Symptoms etc.), thrombocytopenia (less than 0.1%, initial symptoms: petechiae, purpura, etc.) may occur, so if you do observe thoroughly, such as regular examination, Discontinue and take appropriate measures. Liver disorder Jaundice (less than 0.1%), AST (GOT), ALT (GPT), Al - P rise (each less than 0.1 to 5%) etc may appear, so observe thoroughly If abnormalities are observed, discontinue administration and take appropriate measures. Renal disorder Severe kidney injury (less than 0.1%) such as acute renal failure may appear, so observe thoroughly by conducting an examination regularly and if abnormality is found, administration is stopped and appropriate Take action. Colitis Serious colitis accompanied by bloody stools such as pseudomembranous colitis (less than 0.1%) may occur. If abdominal pain or frequent diarrhea appears, administration should be discontinued and appropriate measures should be taken. Interstitial pneumonia, PIE syndrome Interstitial pneumonia accompanied by fever, cough, dyspnea, chest X-ray abnormality, eosinophilia etc., PIE syndrome (less than 0.1% each), etc. may appear, so when such symptoms appear Discontinue administration and take appropriate measures such as administration of adrenocortical hormone drugs. Medicinal pharmacology Antibacterial action The antimicrobial spectrum extends over a wide range of gram-positive bacteria and gram-negative bacteria, particularly in the case of gram-positive cocci, streptococci, pneumococci, for gram-negative bacilli, for Escherichia coli, Klebsiella, Proteus, Morganella morganii, Providencia, Haemophilus influenzae In addition to showing strong antibacterial activity, it shows excellent antibacterial activity against anaerobic bacteria including Citrobacter, Enterobacter, Serratia, Peptostreptococcus, Bacteroides and Prebotera · melaninogenica. The mode of action is bactericidal It is stable to β-lactamase produced by various bacteria and shows excellent antibacterial activity against β-lactamase-producing bacteria Mechanism of action The mechanism of action is inhibition of synthesis of the bacterial cell wall, it has the strongest affinity to penicillin-binding protein (PBP) 1b, then 1a, 3. In addition, outer membrane permeability of Gram negative bacteria is good